HOTH - Hoth stock rises ~20% as Alzheimer's drug shows promise in mice study

• Hoth Therapeutics ( NASDAQ: HOTH ) stock rose ~20% on Wednesday after it reported proof-of-concept data for Alzheimer's disease (AD) drug HT-ALZ in mouse model.
• The company said the proof-of-concept data was generated using cognitive and behavioral assessments in an AD mouse model (aged APP/PS1+/- mice), supporting the therapeutic cognitive potential of HT-ALZ after chronic oral dosing of 20mg/kg and 40mg/kg of HT-ALZ.
• The research was conducted under an agreement between the company and Washington University in St. Louis.
• HT-ALZ is being developed to treat dementia related to AD.
• Hoth noted that the longer treatment before beginning of testing is improving performance of more mice in the water maze and appears to have a positive effect on anxiety-like behavior in the elevated plus maze.
• The groups of mice treated with the higher doses, 20mg/kg and 40mg/kg of HT-ALZ, appear to have the most benefit, with the 20mg group already showing significant improvement in spatial memory in the water maze, according to the company.
• Hoth added that the elevated plus maze test is one of the most widely used tests for measuring anxiety-like behavior.

For further details see: